Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms | Zendy

M. Alejandra Tortorici | Zendy; Martina Beltramello | Zendy; Florian A. Lempp | Zendy; Dora Pinto | Zendy; Ha V. Dang | Zendy; Laura E. Rosen | Zendy; Matthew McCallum | Zendy; John E. Bowen | Zendy; Andrea Minola | Zendy; Stefano Jaconi | Zendy; Fabrizia Zatta | Zendy; Anna De Marco | Zendy; Barbara Guarino | Zendy; Siro Bianchi | Zendy; Elvin J. Lauron | Zendy; Heather Tucker | Zendy; Jiayi Zhou | Zendy; Alessia Peter | Zendy; Colin HavenarDaughton | Zendy; Jason A. Wojcechowskyj | Zendy; James Brett Case | Zendy; Rita E. Chen | Zendy; Hannah Kaiser | Zendy; Martin Montiel-Ruiz | Zendy; Marcel Meury | Zendy; Nadine Czudnochowski | Zendy; Roberto Spreafico | Zendy; Josh R. Dillen | Zendy; Cindy Ng | Zendy; Nicole Sprugasci | Zendy; Katja Culap | Zendy; Fabio Benigni | Zendy; Rana Abdelnabi | Zendy; Caroline S. Foo | Zendy; Michael Schmid | Zendy; Elisabetta Cameroni | Zendy; Agostino Riva | Zendy; Arianna Gabrieli | Zendy; Massimo Galli | Zendy; Matteo Samuele Pizzuto | Zendy; Johan Neyts | Zendy; Michael Diamond | Zendy; Herbert W. Virgin | Zendy; Gyorgy Snell | Zendy; Davide Corti | Zendy; Katja Fink | Zendy; David Veesler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Author(s) -

M. Alejandra Tortorici,

Martina Beltramello,

Florian A. Lempp,

Dora Pinto,

Ha V. Dang,

Laura E. Rosen,

Matthew McCallum,

John E. Bowen,

Andrea Minola,

Stefano Jaconi,

Fabrizia Zatta,

Anna De Marco,

Barbara Guarino,

Siro Bianchi,

Elvin J. Lauron,

Heather Tucker,

Jiayi Zhou,

Alessia Peter,

Colin HavenarDaughton,

Jason A. Wojcechowskyj,

James Brett Case,

Rita E. Chen,

Hannah Kaiser,

Martin Montiel-Ruiz,

Marcel Meury,

Nadine Czudnochowski,

Roberto Spreafico,

Josh R. Dillen,

Cindy Ng,

Nicole Sprugasci,

Katja Culap,

Fabio Benigni,

Rana Abdelnabi,

Caroline S. Foo,

Michael Schmid,

Elisabetta Cameroni,

Agostino Riva,

Arianna Gabrieli,

Massimo Galli,

Matteo Samuele Pizzuto,

Johan Neyts,

Michael Diamond,

Herbert W. Virgin,

Gyorgy Snell,

Davide Corti,

Katja Fink,

David Veesler

Publication year - 2020

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.abe3354

Subject(s) - antibody , covid-19 , virology , epitope , severe acute respiratory syndrome , coronavirus , biology , effector , limiting , receptor , chemistry , immunology , medicine , disease , biochemistry , outbreak , pathology , infectious disease (medical specialty) , mechanical engineering , engineering

Efficient therapeutic options are needed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 September 2020. We report the isolation and characterization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-CoV-2 challenge. Cryo-electron microscopy structures show that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 also locks the spike in a closed conformation by recognition of a quaternary epitope spanning two adjacent receptor-binding domains. Antibody cocktails that include S2M11, S2E12, or the previously identified S309 antibody broadly neutralize a panel of circulating SARS-CoV-2 isolates and activate effector functions. Our results pave the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the emergence of viral escape mutants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research